 Karyopharm Therapeutics Inc NASDAQ: KPTI and the Menarini Group entered an exclusive licensing agreement whereby Menarini will commercialize Karyopharms Nexpovio selinexor in Europe and other key global territories. Under the agreement terms, Menarini received exclusive rights to commercialize Nexpovio for oncology indications in the European Union and other European countries, Latin America and other key countries. 